{
    "clinical_study": {
        "@rank": "141394", 
        "arm_group": [
            {
                "arm_group_label": "Outpatient HiDAC Consolidation Administration", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients are treated with high dose cytarabine (HiDAC) for consolidation of AML in the outpatient setting.  Cytarabine will be administered in a dose of 1.5 grams/m2/day as an intravenous infusion over 3 hours for 6 consecutive days.  Toxicity will be compared with historical controls.  Quality of life will be compared with inpatient controls."
            }, 
            {
                "arm_group_label": "Inpatient Quality of Life Comparison Group", 
                "arm_group_type": "Other", 
                "description": "Any patient who declines to participate as an outpatient or who is not eligible for participation in the outpatient portion of the study can be approached to participate in the inpatient quality of life comparison.  These patients will complete quality of life questionnaires while receiving standard of care inpatient HiDAC consolidation therapy."
            }
        ], 
        "brief_summary": {
            "textblock": "High-dose cytarabine (HiDAC) is considered a standard chemotherapy treatment for patients\n      with acute myeloid leukemia.  However, most patients receiving this therapy are required to\n      be admitted to the hospital during their treatment course.\n\n      The purpose of this study is to compare the safety and cost of high-dose cytarabine\n      treatment given in an in-patient setting versus an out-patient setting."
        }, 
        "brief_title": "Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML)", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Myeloid Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "detailed_description": {
            "textblock": "The primary objective of this study is to:\n\n      \u2022 To determine the incidence of grade 3 to 5 non-hematologic toxicity of high-dose\n      cytarabine (HiDAC) for AML consolidation administered in an outpatient setting.\n\n      The secondary objectives of this study are to:\n\n        -  To determine cost effectiveness of outpatient HiDAC consolidation versus the standard\n           of care inpatient HiDAC consolidation.\n\n        -  Evaluate patient quality of life (QOL) with this outpatient regimen in comparison to\n           that with the standard inpatient regimen."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Inclusion Criteria for Outpatient Administration of HiDAC\n\n          -  Unequivocal diagnosis of AML (>20% blasts in the bone marrow based on the WHO\n             classification), excluding M3 (acute promyelocytic leukemia).\n\n          -  Documented complete remission (CR) following induction chemotherapy as defined as\n             (18):\n\n          -  Bone marrow with <5% blasts; absence of blasts with Auer rods\n\n          -  Absolute neutrophil count >1000/mcL\n\n          -  Platelets >100,000/mcL\n\n          -  Independence of red cell transfusions\n\n          -  Absence of extramedullary disease\n\n          -  Age \u2265 55 years.\n\n          -  Relapsed AML patients are eligible as long as they meet other inclusion and exclusion\n             criteria.\n\n          -  Good performance status of (ECOG 0-2), see appendix 15.3.\n\n          -  Adequate renal and hepatic function (Cr \u2264 1.2, alkaline phosphatase <3.0 x upper\n             limit of normal, total bilirubin <1.5 x upper limit of normal unless there is a\n             history of Gilbert's disease).\n\n        Inclusion Criteria for Quality of Life Comparison Group\n\n          -  All patients decline to participate as an out-patient or who are not eligible for\n             participation in the out-patient portion of the study will be approached to\n             participate in the QOL comparison.\n\n          -  Age \u2265 18 years\n\n        Exclusion Criteria:\n\n        Exclusion Criteria for All Patients\n\n          -  Active, uncontrolled viral, bacterial, or fungal infection.\n\n          -  Documented CNS leukemia.\n\n          -  If unable to do a reliable cerebellar examination for monitoring of neurotoxicity.\n\n          -  History of prior autologous or allogeneic bone marrow/stem cell transplant.\n\n          -  New York Heart Association class III/IV congestive heart failure, see appendix 15.4,\n             or active ischemic heart disease.\n\n          -  Pregnant or lactating women (women and men of childbearing age should use effective\n             contraception).\n\n          -  Concomitant active malignancy requiring treatment with cytotoxic chemotherapy or\n             radiation therapy.  (Ongoing hormonal therapy for the treatment of malignancy would\n             not exclude patients from this trial.)\n\n          -  Time period of greater than 10 weeks between initiation of induction chemotherapy and\n             day 1 of the first cycle of consolidation chemotherapy.\n\n          -  Patients seropositive for infection with Human Immunodeficiency Virus (HIV) are\n             excluded due to potential for serious infectious complications associated with T-cell\n             suppressive therapy in these patients."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "55 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02101983", 
            "org_study_id": "35606"
        }, 
        "intervention": {
            "arm_group_label": [
                "Outpatient HiDAC Consolidation Administration", 
                "Inpatient Quality of Life Comparison Group"
            ], 
            "intervention_name": "Cytarabine", 
            "intervention_type": "Drug", 
            "other_name": [
                "AraC", 
                "Cytosar U", 
                "Cytosine aribinoside", 
                "Arabinosylcytosine", 
                "Cytarabine sterile", 
                "1-B-Arabinoe-furanosyl-cytosine"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Cytarabine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Acute myeloid leukemia", 
            "outpatient consolidation treatment"
        ], 
        "lastchanged_date": "March 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14642"
                }, 
                "name": "University of Rochester"
            }, 
            "investigator": {
                "last_name": "Deborah Mulford, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia", 
        "overall_contact": {
            "email": "Deborah_Mulford@urmc.rochester.edu", 
            "last_name": "Deborah Mulford, MD"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "complete blood count, platelet count and differential.", 
            "measure": "complete blood count", 
            "safety_issue": "Yes", 
            "time_frame": "twice weekly for two months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02101983"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Evaluate the patient's quality of life with this outpatient regimen in comparison to that with the standard regimen.", 
            "measure": "completion of quality of life form", 
            "safety_issue": "No", 
            "time_frame": "twice during two months"
        }, 
        "source": "University of Rochester", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Rochester", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2011", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}